(Elotuzumab)Biosimilar Reference Antibody-GS40216 新品

货号：GS40216

Elotuzumab is a humanized immunoglobulin G1 (IgG1) monoclonal antibody approved for the treatment of multiple myeloma. It represents a first-in-class immunostimulatory therapy with a unique dual mechanism of action. First, it directly binds to SLAMF7 on myeloma cells. Second, and critically, it simultaneously binds to Fc gamma receptors (FcγR) on natural killer (NK) cells via its Fc portion. This dual engagement specifically activates NK cells and directs their cytotoxic activity against the SLAMF7-positive myeloma cells, primarily through antibody-dependent cellular cytotoxicity (ADCC). Unlike most monoclonal antibodies, elotuzumab does not directly induce apoptosis or block a signaling pathway on the tumor cell itself.